Poléčebná hodnota TGF-beta1 predikuje vyšší postradiační morbiditu u pacientů s pokročilými ORL malignitami

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F05%3AA0900HLJ" target="_blank" >RIV/61988987:17110/05:A0900HLJ - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Posttreatment plasma transforming growth factor beta 1 level predicts for late morbidity in parients with advanced head and neck cancer

Popis výsledku v původním jazyce

Methods and materials Between 2001-2002, 36 patients with advanced inoperable squamous head and neck cancer treated with radiotherapy with or without simultaneous chemotherapy were evaluated for their plasma TGF-b1 levels prior to the treatment, in the middle of the radiotherapy course and at the end of the treatment. The patients were assessed for treatment response and late morbidity. Results There were 29 eligible patients (pts), the rest being lost of follow-up. Of these 29 pts, 18 achieved completeresponse, 8 partial response and three pts progressed primarily. After a median follow-up of 16 months (range 3-28), we recorded 16 cases of grade > 1 late morbidity. We found that posttreatment elevated plasma TGF-b1 level predicts late morbidity grade>1 (p=0,05 see Graph 1) rather than pretreatment level (p=0,062). Conclusion Posttreatment plasma TGF-beta 1 level can predict late morbidity grade >1 in advanced head and neck cancer treated with radio(chemo)therapy.

Název v anglickém jazyce

Posttreatment plasma transforming growth factor beta 1 level predicts for late morbidity in parients with advanced head and neck cancer

Popis výsledku anglicky

Methods and materials Between 2001-2002, 36 patients with advanced inoperable squamous head and neck cancer treated with radiotherapy with or without simultaneous chemotherapy were evaluated for their plasma TGF-b1 levels prior to the treatment, in the middle of the radiotherapy course and at the end of the treatment. The patients were assessed for treatment response and late morbidity. Results There were 29 eligible patients (pts), the rest being lost of follow-up. Of these 29 pts, 18 achieved completeresponse, 8 partial response and three pts progressed primarily. After a median follow-up of 16 months (range 3-28), we recorded 16 cases of grade > 1 late morbidity. We found that posttreatment elevated plasma TGF-b1 level predicts late morbidity grade>1 (p=0,05 see Graph 1) rather than pretreatment level (p=0,062). Conclusion Posttreatment plasma TGF-beta 1 level can predict late morbidity grade >1 in advanced head and neck cancer treated with radio(chemo)therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

NEOPLASMA

ISSN

0028-2685

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

5

Strana od-do

—

Kód UT WoS článku

000232222100007

EID výsledku v databázi Scopus

—